Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BV100 plus polymyxin B versus best available therapy for ventilator-associated bacterial pneumonia due to carbapenem-resistant Acinetobacter baumannii
2022-002856-37Phase 2Completed
- Sponsor
- BioVersys AG
- Start
- Dec 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BV100 and polymyxin B in ventilator-associated pneumonia (VAP) and Ventilator-associated bacterial pneumonia due to carbapenem-resistant Acinetobacter baumannii (CRAB-VAP) (2 arms), sponsored by BioVersys AG. Primary endpoint: Pharmacokinetic properties of rifabutin, 25-OH-deacetyl-rifabutin, and DMI in plasma. Started Dec 2022; status: completed.
02
Drugs
BV100polymyxin B
03
Conditions
ventilator-associated pneumonia (VAP)Ventilator-associated bacterial pneumonia due to carbapenem-resistant Acinetobacter baumannii (CRAB-VAP)
Beyond the preview
Go deeper on 2022-002856-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002856-37.